Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea

Inclusion Criteria: * Subject with facial vascular rosacea with flushing, permanent redness, telangiectasias and at least 3 papules and/or pustules (this last criterion for at least 10 subjects per group) * Subject starting local treatment for rosacea (Ivermectin or metronidazole) * Female aged 18 to 65 years old, * Subject of all types of skin * Subject of I to IV phototype. * Subject accepting not to use any type of facial skin care other than the study product * Subject willing to keep their usual habits and products (hygiene products, sunscreen, and make-up, if applicable) * Subject willing to avoid sun exposure during the study period * Subject willing to actively participate in the study and to come to the scheduled visits * Subject that has signed informed consent Exclusion Criteria: * Pregnant or breastfeeding woman * Subject showing cutaneous marks on the experimental areas, which could interfere with the assessment of skin reactions (pigmentation troubles, scar elements, over-developed pilosity, ephelides and naevi in too great quantity, sunburn) * Subject with documented allergy or reactivity to products of the same category than the tested one * Subject with documented allergies to study product components * Subject with history of malignant melanomas (Dubreuilh melanosis…) * Subject with unbalanced hormonal treatment * Subject with forecast of initiation of a hormonal treatment or change of the usual hormonal treatment during the study period * Subject with forecast of sun or UVA exposure (UV lamps) during the study period * Subject not willing to use sun protective clothes orhat if exposed to the sun * Subject not willing to respect the methods of use of the treatment, study product and sunscreen * Subject with anti-ageing or aesthetic treatment during the last 6 months: botox or botox like products, peelings, plastic surgery, hyaluronic acid treatment, Plasma Rich Platelets treatment, or any other specific treatments prone to change the skin aspect * Subject with antibiotic, anti-allergic, anti-inflammatory treatment or treatment with patent medicines containing Vitamin A acid or its derivatives within 4 weeks and during the study (if therapeutic requirement: exclusion foreseen), * Subject with systemic disorder: cardiovascular, pulmonary, digestive, neurologic, psychiatric, genital, urinary, haematological, endocrine * Subject presenting chronic diseases with impact on skin * Subject who has undergone a bilateral mastectomy with lymph node removal, a unilateral mastectomy with lymph node removal within the last year, or a bilateral axillary lymph node removal, * Subject with a history of immune deficiency or auto-immune disease, treated for malignancy within 6 months prior to enrolment or who are currently under treatment for asthma or diabetes, forecast of vaccination during the test period or last vaccination within 3 weeks before the study. * Subject receiving local treatment for rosacea (cyclins, isotretinoin) or who has undergone local active treatment for rosacea (erythromycin, metronidazole, benzoyl peroxide, ivermectin) within 4 weeks before inclusion in the study * Subject who has had oral treatment with metronidazole or cyclins within 4 weeks before inclusion in the study * Subject who has had topical or oral anti-inflammatory and/or antiallergy treatment (corticosteroid, antihistamine, anti-inflammatory drugs, immunosuppressives) within 4 weeks before inclusion in the study * Subject who has had oral treatment with retinoids within 2 months before inclusion in the study * Subject currently receiving electrocoagulation or laser treatment for telangiectasia